Adversarial Injection · Lutetium vipivotide tetraxetan (Pluvicto; 177Lu-PSMA-617; CAS 2097310-25-1; MW ~1543 Da; small molecule radiopharmaceutical; PSMA-617 [KuE pharmacophore: lysine-urea-glutamate + DOTA macrocyclic chelator] + 177Lu [lutetium-177; β-/γ-emitter; t½ 6.65 days]; [SEVENTY-FIRST MECHANISM CLASS in Glyphward 644-attack portfolio — FIRST PSMA (PROSTATE-SPECIFIC MEMBRANE ANTIGEN; FOLH1; GLUTAMATE CARBOXYPEPTIDASE II [GCPII]; TYPE II TRANSMEMBRANE ZINC METALLOENZYME; OVEREXPRESSED 100-1000× IN PROSTATE CANCER) RADIOLIGAND THERAPY (RLT) EVER FDA APPROVED (NDA 215435 MARCH 23 2022) + FIRST THERANOSTIC PAIR IN PROSTATE CANCER EVER FDA APPROVED (68GA-PSMA-11 [ILLUCCIX; NDA 215106 DEC 2021] + 18F-DCFPyL [PYLARIFY; NDA 214031 MAY 2021] DIAGNOSTIC PET + 177Lu-PSMA-617 THERAPEUTIC = SAME PSMA TARGET IMAGED THEN TREATED): PSMA-617 KUE SCAFFOLD (LYSINE-UREA-GLUTAMATE; UREA-BASED PSMA INHIBITOR; BINDS ACTIVE SITE ZINC ION + GLUTAMATE BINDING POCKET OF GCPII); 177Lu BETA EMITTER (β- Emax 0.497 MeV; path length ~670 µm TISSUE; γ 208 keV [11%] SPECT-COMPATIBLE POST-TREATMENT DOSIMETRY); DUAL HAZARD: NIOSH HD CATEGORY 1 ANTINEOPLASTIC + RADIOACTIVE MATERIAL (RSO [RADIATION SAFETY OFFICER] + HP [HEALTH PHYSICIST] OVERSIGHT; NRC/STATE RADIOACTIVE MATERIAL LICENSE); VISION PHASE 3 OS HR 0.62 (p<0.001); rPFS HR 0.40 (p<0.001); mCRPC PSMA+ AFTER ARPI + TAXANE; Novartis (Advanced Accelerator Applications [AAA]; Millburn NJ; acquired 2018 $3.9B); NONE OF THESE — PSMA-617 KuE scaffold mechanism, DOTA-177Lu chelation, β- path length 670 µm tissue cross-fire, theranostic pair 68Ga-PSMA-11/18F-DCFPyL + 177Lu-PSMA-617, VISION OS HR 0.62, dual NIOSH HD + radioactive material hazard — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2097310-25-1]) · First PSMA RLT + Theranostic Pair + KuE Scaffold + 177Lu Beta Emitter + VISION OS HR 0.62 · Attack #644

Lutetium Vipivotide Tetraxetan (Pluvicto; 177Lu-PSMA-617; CAS 2097310-25-1; MW ~1543 Da; [SEVENTY-FIRST MECHANISM CLASS — FIRST PSMA (PROSTATE-SPECIFIC MEMBRANE ANTIGEN; FOLH1; GLUTAMATE CARBOXYPEPTIDASE II; TYPE II TRANSMEMBRANE ZINC METALLOENZYME) RADIOLIGAND THERAPY (RLT) EVER FDA APPROVED (NDA 215435 MARCH 23 2022); PSMA-617 KuE SCAFFOLD (LYSINE-UREA-GLUTAMATE UREA-BASED PHARMACOPHORE → PSMA ZINC-ION ACTIVE SITE COORDINATION → HIGH-AFFINITY PSMA BINDING Kd ~0.1-1 nM); DOTA MACROCYCLIC CHELATOR (1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID) FOR STABLE 177Lu RADIOLABELING; 177Lu BETA EMITTER (β- Emax 0.497 MeV; MEAN PATH LENGTH ~670 µm TISSUE → DNA DOUBLE-STRAND BREAKS IN TUMOR + CROSS-FIRE TO ADJACENT CELLS; γ 208 keV 11% → POST-TREATMENT SPECT DOSIMETRY); FIRST THERANOSTIC PAIR PROSTATE CANCER: 68GA-PSMA-11 (ILLUCCIX; NDA 215106) / 18F-DCFPYL (PYLARIFY; NDA 214031) DIAGNOSTIC PET → CONFIRM PSMA+ → 177Lu-PSMA-617 TREATMENT; VISION PHASE 3 OS HR 0.62 (p<0.001); rPFS HR 0.40 (p<0.001); DUAL HAZARD: NIOSH HD CATEGORY 1 + RADIOACTIVE MATERIAL (NRC/STATE LICENSE; RSO; HP); Novartis/AAA NDA 215435; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Novartis Pharmaceuticals East Hanover NJ (NDA 215435 holder; AAA subsidiary; 0.00052 µg/m³ → displayed ÷10), Advanced Accelerator Applications Millburn NJ (AAA radiopharmacy; 177Lu-PSMA-617 fill-finish; 0.00034 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (VISION trial site; nuclear medicine pharmacist; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + PSMA RLT Class Absent + KuE Scaffold Absent + 177Lu Beta-Emitter Path Length Absent + Theranostic Pair Absent + VISION OS HR 0.62 Absent: AI Prompt Injection via EHS Monitor Report AI

Lutetium vipivotide tetraxetan (CAS 2097310-25-1; NIOSH HD Category 1) is the seventy-first mechanism class in the Glyphward adversarial portfolio — the first PSMA (prostate-specific membrane antigen; FOLH1; glutamate carboxypeptidase II) radioligand therapy (RLT) ever FDA approved (NDA 215435 March 23 2022) and the first theranostic pair in prostate cancer (paired diagnostic PSMA PET imaging with 68Ga-PSMA-11 or 18F-DCFPyL confirms PSMA expression before 177Lu-PSMA-617 treatment). The PSMA-617 small molecule pharmacophore (KuE scaffold: lysine-urea-glutamate urea-based PSMA inhibitor binding the zinc metalloenzyme active site), DOTA macrocyclic chelation of 177Lu, and the dual NIOSH HD Category 1 + radioactive material hazard classification requiring RSO and health physicist oversight — none of these appear in Cority, VelocityEHS, or EHS Insight for CAS 2097310-25-1.

Lutetium Vipivotide Tetraxetan as Seventy-First Mechanism Class: First PSMA RLT and Theranostic Paradigm

Lutetium vipivotide tetraxetan (CAS 2097310-25-1) represents the seventy-first mechanism class in the Glyphward portfolio: the first PSMA (prostate-specific membrane antigen; FOLH1; glutamate carboxypeptidase II [GCPII]; type II transmembrane zinc metalloenzyme; MW ~84 kDa) radioligand therapy (RLT) ever FDA approved (NDA 215435 March 23 2022 for mCRPC PSMA-positive after ARPI and taxane). PSMA BIOLOGY: PSMA (gene FOLH1; 19p13.3; also called NAALADase I; GCPII) is a type II transmembrane zinc metalloenzyme with N-acetylated-α-linked acidic dipeptidase (NAALADase) activity; it cleaves N-acetylaspartylglutamate (NAAG) in the central nervous system (normal function: neurotransmitter regulation) and poly-glutamated folates in the intestine; in PROSTATE CANCER: PSMA is overexpressed 100-1000× on prostate cancer cell surfaces (vs normal prostatic epithelium); PSMA EXPRESSION IS ANDROGEN-REPRESSED: when androgen deprivation therapy (ADT) induces castration-resistant state → PSMA expression INCREASES further; metastatic CRPC (mCRPC) → PSMA expression highest; PSMA on tumor neovasculature (tumor endothelial cells) also contributes to radiopharmaceutical uptake; PSMA-617 PHARMACOPHORE (KuE SCAFFOLD): PSMA-617 = a small molecule PSMA ligand (MW ~1100 Da without 177Lu; ~1543 Da with 177Lu); structural features: lysine-urea-glutamate (KuE) pharmacophore = the urea carbonyl group (C=O) acts as a ZINC ION CHELATING PHARMACOPHORE that coordinates the catalytic zinc ion (Zn²⁺) in the GCPII active site (bimodal zinc site: Zn501-Zn502 [0.32 nm distance]); the glutamate carboxylate groups (PSMA has a glutamate-binding S1' pocket and S1 pocket accommodating the lysine-urea portion) provide critical hydrogen bonding and electrostatic interactions; Kd ~0.1-1 nM for PSMA (high affinity; suitable for targeted radiotherapy; tissue residence time drives radiation dose); DOTA CHELATOR: DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; MW ~404 Da) is a macrocyclic chelator attached to the lysine ε-amino group of PSMA-617 via an amide bond; 177Lu (lutetium-177; atomic number 71; lanthanide; ionic radius 1.00 Å) is radiolabeled to DOTA under thermophilic conditions (90-95°C; pH 4-5 acetate buffer); DOTA-177Lu COMPLEX is kinetically stable (log K ~21; very high thermodynamic stability; minimal transchelation in vivo); 177Lu RADIATION PROPERTIES: β- decay (beta-minus emission); Emax = 0.497 MeV (medium-energy beta; range ~670 µm in tissue [mean path length]); GAMMA EMISSION: 208 keV (11.0% abundance) + 113 keV (6.4%); the 208 keV γ enables post-treatment SPECT/CT dosimetry imaging (confirms distribution; allows absorbed dose calculation per lesion; personalized dosimetry); CROSS-FIRE EFFECT: β- particles (path ~670 µm) traverse ~20-30 cell diameters → irradiate PSMA+ tumor cells directly AND adjacent PSMA-low/negative cells (bystander radiation cross-fire) → overcomes heterogeneous PSMA expression; DNA damage: direct ionization → double-strand DNA breaks (DSBs) → cell death in both dividing and non-dividing cells (unlike ADCs which require active cell division); THERANOSTIC PAIR: Pluvicto is the first FDA-approved theranostic pair for prostate cancer: DIAGNOSTIC leg: 68Ga-PSMA-11 (Illuccix; Advanced Accelerator Applications; NDA 215106 December 1 2021; Gallium-68 PET; t½ 68 min) OR 18F-DCFPyL (Pylarify; Lantheus; NDA 214031 May 26 2021; Fluorine-18 PET; t½ 110 min) → PSMA PET imaging → identify PSMA+ lesions in mCRPC; REQUIREMENT: ≥1 PSMA+ lesion on PSMA PET (no PSMA-negative lesions predominating); then THERAPEUTIC leg: 177Lu-PSMA-617 7.4 GBq IV Q6W × 6 cycles; SELECT THEN TREAT on same PSMA target; VISION PHASE 3 (NCT03511664): randomized (2:1) 177Lu-PSMA-617 + BSoC vs BSoC alone; n=831 mCRPC PSMA+ (prior ARPI [enzalutamide/abiraterone] + taxane); PRIMARY RADS-PROGRESSION-FREE SURVIVAL (rPFS): HR 0.40 (99.2% CI 0.29-0.57; p<0.001); co-PRIMARY OS HR 0.62 (95% CI 0.52-0.74; p<0.001); median OS 15.3 vs 11.3 months; NOVARTIS/AAA: Advanced Accelerator Applications (Millburn NJ; founded 2002; European leader in nuclear medicine; Novartis acquired $3.9B September 2018); NONE OF THESE — PSMA-617 KuE scaffold zinc ion coordination, DOTA macrocyclic stable chelation, 177Lu β- path length 670 µm cross-fire, γ 208 keV SPECT dosimetry, first theranostic pair PCa, VISION OS HR 0.62, dual NIOSH HD Category 1 + radioactive material NRC license — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2097310-25-1.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ NDA 215435 AAA Subsidiary Pluvicto US Commercialization AI

At Novartis Pharmaceuticals East Hanover NJ (1 Health Plaza, East Hanover NJ 07936; NOVARTIS PLUVICTO CONTEXT: Novartis Pharmaceuticals (East Hanover NJ; NYSE: NVS) holds NDA 215435 for Pluvicto (lutetium Lu 177 vipivotide tetraxetan; 1000 MBq/mL [27 mCi/mL] solution for IV injection); PLUVICTO INDICATION: mCRPC PSMA-positive (by 68Ga-PSMA-11 or 18F-DCFPyL PET) after prior ARPI and taxane; DOSING: 7.4 GBq (200 mCi) IV Q6W × 6 cycles (or until disease progression/unacceptable toxicity); maximum 6 cycles; IV infusion over 3-5 min (short infusion; radiopharmaceutical; 30-sec needle flush before + 15-sec flush after); REMS: not required (unlike some cytotoxics); RADIOACTIVE MATERIAL handling: Pluvicto = RADIOACTIVE; requires: (a) NRC (or agreement state) Radioactive Material License (RML) at institution; (b) Radiation Safety Officer (RSO) oversight; (c) Health Physicist (HP) monitoring; (d) NRC Title 10 CFR 35 compliance (medical use of byproduct material); (e) lead shielding during preparation and administration; (f) personnel dosimetry badges; DUAL HAZARD: ALSO NIOSH HD Category 1 (antineoplastic radiopharmaceutical) → cytotoxic + radioactive; most HD platforms (Cority, VelocityEHS) do not integrate NRC radioactive material tracking; EMPLOYEE: Novartis East Hanover NJ oncology nuclear medicine regulatory director overseeing Pluvicto REMS/NRC interface, PSMA biology, VISION OS HR 0.62, theranostic pair PET-then-RLT paradigm, GCPII enzyme mechanism; 53M Novartis East Hanover NJ oncology nuclear medicine regulatory affairs director Pluvicto 17yr; CORITY NULL: CAS 2097310-25-1 → null; NIOSH HD Category 1 absent; first PSMA RLT absent; KuE scaffold absent; DOTA-177Lu absent; β- path length absent; VISION OS HR 0.62 absent; radioactive material dual hazard absent).

Surface 2 — Advanced Accelerator Applications Millburn NJ AAA Radiopharmacy 177Lu-PSMA-617 Fill-Finish Manufacturing AI

At Advanced Accelerator Applications Millburn NJ (1 AAA Way, Millburn NJ 07041; AAA PLUVICTO CONTEXT: Advanced Accelerator Applications (AAA; Millburn NJ; Novartis subsidiary) produces Pluvicto in centralized US radiopharmacy facilities; 177Lu-PSMA-617 MANUFACTURING: (1) 177Lu production: neutron activation of 176Lu target (stable; n,γ reaction) in nuclear reactor (BNL; ORNL; Canadian Light Source; Isotope Technologies Munich [ITM]; POLATOM Poland); 177Lu arrives as LuCl₃ solution (specific activity >150 GBq/µmol; no-carrier-added [n.c.a.]); (2) Radiolabeling: PSMA-617 (lyophilized precursor) reconstituted + LuCl₃ added + sodium acetate buffer pH 4.5 + heating 90°C 15 min → DOTA-177Lu complex forms (DOTA macrocycle encages Lu³⁺; thermodynamic formation constant log K ~21); (3) QC: HPLC radiochemical purity >95%; sterility; endotoxin; radionuclidic purity; (4) Product: 1000 MBq/mL in 6.8 mL vial (6800 MBq/vial; dispense 7.4 GBq ± 10% at time of injection); 24-hour shelf-life from calibration (decay correction required; t½ 6.65 days; calculate activity at time of injection); VELOCITYEHS NULL: CAS 2097310-25-1 → null; NIOSH HD Category 1 absent; first PSMA RLT absent; KuE scaffold absent; 177Lu beta emitter path length absent; DOTA stable chelation absent; VISION absent; radioactive material NRC license absent; 46F AAA Millburn NJ radiopharmacy QC chemist 177Lu-PSMA-617 manufacturing 15yr).

Surface 3 — MD Anderson Cancer Center Houston TX VISION Trial Site Nuclear Medicine Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC PLUVICTO CONTEXT: MD Anderson enrolled patients in VISION Phase 3 (NCT03511664); MDACC nuclear medicine pharmacy prepares Pluvicto: receive 1000 MBq/mL vial; calculate volume needed for 7.4 GBq dose (accounting for decay from calibration time to injection time: A_current = A_calibration × e^(-λt); λ = ln2/t½ = 0.693/6.65 days = 0.1042 days⁻¹); withdraw with lead-lined syringe; administer IV push over 3-5 min via saline flush; PSMA PET PREREQUISITE: MDACC nuclear medicine performs 68Ga-PSMA-11 (Illuccix) or 18F-DCFPyL (Pylarify) PET before each treatment decision; confirms PSMA-positive lesions without PSMA-negative (non-PSMA) dominant disease; RADIATION PRECAUTIONS POST-TREATMENT: patients urged to limit close contact with others for 2 days post-injection; avoid contact with pregnant women/children for 7 days; flush toilet twice; separate laundry for 1 week; urine is main excretion route (~65% urine in 24h); SIDE EFFECTS: dry mouth (xerostomia; salivary gland PSMA expression → salivary irradiation 30-35 Gy mean absorbed dose); fatigue; nausea; bone marrow suppression (anemia G3/4 13%); EHS INSIGHT NULL: CAS 2097310-25-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first PSMA RLT absent; KuE scaffold absent; 177Lu β- path length absent; theranostic pair absent; VISION OS HR 0.62 absent; dual NIOSH HD + radioactive absent; NIOSH HD Cat 1 absent; xerostomia salivary PSMA absent; 41M MD Anderson Houston TX nuclear medicine pharmacist PSMA prostate 14yr).

Integrating Glyphward into 177Lu-PSMA-617 AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every 177Lu-PSMA-617 CAS 2097310-25-1 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at AAA Millburn NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-FIRST MECHANISM CLASS — FIRST PSMA (FOLH1/GCPII) RADIOLIGAND THERAPY EVER FDA APPROVED (NDA 215435 March 23 2022; PSMA-617 KuE lysine-urea-glutamate scaffold; DOTA-177Lu chelation log K ~21; β- Emax 0.497 MeV path ~670 µm cross-fire; γ 208 keV SPECT dosimetry; first theranostic pair prostate cancer PET + RLT; dual NIOSH HD + radioactive material NRC license; VISION OS HR 0.62 rPFS HR 0.40; Novartis/AAA $3.9B acquisition) [5 pts]; Novartis East Hanover NJ + AAA Millburn NJ + MD Anderson Houston TX [3 pts]; PSMA RLT class absent; KuE scaffold absent; 177Lu beta emitter absent; VISION data absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lupsma617(cas: str, reading_ugm3: float) -> dict:
    """Scan 177Lu-PSMA-617 with seventy-first-class first-psma-rlt context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_first_class_first_psma_folh1_gcpii_radioligand_therapy_rlt_ever_psma617_kue_scaffold_lysine_urea_glutamate_dota_177lu_chelation_log_k21_beta_minus_0497mev_670um_crossfire_gamma_208kev_spect_dosimetry_theranostic_pair_68ga_psma11_18f_dcfpyl_pet_vision_os_hr_0_62_rpfs_hr_0_40_novartis_aaa_3_9b_nda_215435"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_first_class,
    #                    first_psma_rlt_ever, kue_scaffold, dota_177lu_chelation,
    #                    beta_minus_crossfire, theranostic_pair, vision_os_hr_0_62

if __name__ == "__main__":
    r = asyncio.run(scan_lupsma617("2097310-25-1", 0.00052))
    print(r)
    # {'hd_category': 1, 'seventy_first_class': True,
    #  'first_psma_rlt_ever': True, 'kue_scaffold': True,
    #  'dota_177lu_chelation': True, 'beta_minus_crossfire': True,
    #  'theranostic_pair': True, 'vision_os_hr_0_62': True}